Article Text

Download PDFPDF
Oncostability: stability of reconstituted and diluted anticancer medicines for a possible extension of use
  1. Marco Chiumente1,
  2. Melania Rivano2,
  3. Debora Severino3,
  4. Sara Bertoli4,
  5. Anna Rita Gasbarro5,
  6. Rossella Santeramo5,
  7. Alessandra Pasqualini6,
  8. Riccardo Provasi7,
  9. Daniele Mengato8,
  10. Angelo Claudio Palozzo9
  1. 1 Scientific Direction, Italian Society for Clinical Pharmacy and Therapeutics, Milan, Italy
  2. 2 Clinical Oncology Pharmacy, Azienda Ospedaliera Brotzu, Cagliari, Italy
  3. 3 Hospital Pharmacy Department, Ausl Modena, Modena, Italy
  4. 4 Department of Pharmacy, IRCCS National Cancer Institute, Milano, Lombardia, Italy
  5. 5 Hospital Pharmacy Department, University Hospital Policlinico, Bari, Italy
  6. 6 Hospital Pharmacy Department, S.Chiara Hospital, Trento, Italy
  7. 7 Azienda Sanitaria Universitaria Integrata Giuliano Isontina, Trieste, Italy
  8. 8 Hospital Pharmacy Department, Azienda Ospedale – Università of Padova, Padova, Italy
  9. 9 Presidency, SIFaCT President, Italian Society for Clinical Pharmacy and Therapy, Milano, Italy
  1. Correspondence to Dr Melania Rivano, Clinical Oncology Pharmacy, Azienda Ospedaliera Brotzu, Cagliari 09134, Sardegna, Italy; melania.rivano{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

The chemical-physical stability, reported in the Summary of Product Characteristics (SPC), indicates the time parameters within which the manufacturer guarantees the use of the drug once the vial has been handled (in-use stability).

The stability data reported in the SPC are often time limited. An extended time of use of the preparation, without affecting drug stability and safety, would facilitate the organisation of anticancer drug compounding and be economically advantageous due to the possibility of using the residues for subsequent preparations.1 2 A unique source of evidence-based stability data regarding antineoplastic drugs should be a helpful tool for pharmacists. In addition, given the lack of homogeneity in the interpretation of data in the literature, it is necessary to harmonise the methodology …

View Full Text


  • Contributors MC, ARG, RS, AP, RP and ACP were responsible for study conception and design; MR, DS and SB were responsible for acquisition of data; MC, MR, DS and SB were responsible for data analysis and drafting; MC, DM and ACP were responsible for data quality assurance, revision of the manuscript and final approval of the version to be published.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; internally peer reviewed.